Advancements in Myeloproliferative Neoplasm Treatments

This chapter explores the evolution of treatment strategies for myeloproliferative neoplasms in low-risk patients, highlighting newer therapies like pegylated interferons and ruxolitinib. The discussion focuses on the significance of allele burden, JAK2 mutation awareness, and how these factors influence patient treatment decisions and long-term outcomes. Additionally, the chapter emphasizes the role of patient communication and lifestyle factors in managing the disease.